Precision Treatment of HR+ HER2- Advanced Breast Cancer Based on SNF Molecular Subtyping

NCT06561022 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

260

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Fluzoparib
DRUG: Everolimus
DRUG: Fulvestrant
DRUG: Abemaciclib

Sponsor

Fudan University